The AMPLICOR Enterovirus Test was evaluated with 103 cerebrospinal fluid (CSF) specimens. Twentyseven CSF specimens were culture positive. With the AMPLICOR test, enterovirus RNA was detected in 34 specimens. Compared with culture, the AMPLICOR test gave a sensitivity of 96.3% and a specificity of 100%. The sensitivity of culture was 79.4% in comparison with the AMPLICOR test.
Clinical presentation of enterovirus meningitis may be difficult to distinguish from that of meningitis due to bacteria, fungi, or other viruses, resulting in unnecessary hospitalization and inappropriate treatment. Therefore, specific and rapid diagnosis of enterovirus meningitis appears to be of paramount importance for patient management (3). Attempts to isolate enteroviruses from cerebrospinal fluid (CSF) are laborious, typically involve observation for at least 3 weeks before being reported as negative, and are frequently unsuccessful (4, 5) . Furthermore, culture may not be optimal for detecting the organism because of the difficulty in transporting live organisms. Therefore, PCR techniques have been introduced for the detection of enteroviruses in CSF (7, (10) (11) (12) . Recently a new molecular assay (AMPLICOR Enterovirus Test; Roche Molecular Systems, Branchburg, N.J.) has been introduced (8, 15) .
In this study, 103 CSF samples were investigated retrospectively. All samples had been collected from 103 patients who had clinical presentations compatible with enterovirus meningitis and were admitted to the University Hospitals in Graz, Austria; Frankfurt am Main, Federal Republic of Germany; and Zagreb, Republic of Croatia, during the 1995 summer season. The mean age of the patients was 11.5 years (range, 1 month to 48 years). Lumbar punctures were done at a mean of 26 h (range, 13 to 70 h) after the onset of illness. All samples were obtained prior to therapy.
All CSF specimens were processed with the AMPLICOR Enterovirus Test following the manufacturer's instructions. Sensitivity of the AMPLICOR Enterovirus Test was determined by detection of RNA extracted from viral stocks ranging from 10 3 to 10 Ϫ2 50% tissue culture infective dose (TCID 50 ). Specificity was determined with normal human CSF, uninfected human fibroblast cells, DNAs from human leukocytes, and a large variety of nonenterovirus meningitis pathogens.
For enterovirus isolation, 200 l of CSF was inoculated onto human colonic carcinoma (CaCo-2) cells (European Collection of Cell Cultures, Salisbury, United Kingdom) as previously reported (13, 14) .
For an in-house PCR assay, enterovirus RNA was isolated from 100 l of CSF with the QIAamp HCV Kit (Qiagen, Hilden, Federal Republic of Germany) according to the manufacturer's recommendations. Reverse transcription and amplification of cDNA were done as previously described (2, 16). The digoxigenin-labeled amplification products were analyzed with the Enzymun-Test DNA Detection assay (Boehringer) on the ES 300 instrument (9 From a total of 103 CSF specimens, 27 (26%) were positive for enteroviruses in cell cultures. Enteroviral RNA was detected by the AMPLICOR test in 34 (33%) of the 103 CSF specimens. Eight specimens were AMPLICOR positive and culture negative, and one of the specimens was AMPLICOR negative and culture positive. Repeat testing of all discordant specimens gave results identical to those of the initial test. The in-house PCR assay gave positive results for all of the AM-PLICOR positives as well as for the one specimen which was AMPLICOR negative and culture positive. It gave negative results for all specimens which were negative by both culture and the AMPLICOR test.
The AMPLICOR test proved to be very robust and reproducible; all runs were valid, and the optical density values for the positive and negative groups of specimens were widely separated. Compared with culture, the AMPLICOR test gave a sensitivity of 96.3%. Sensitivity of culture was 79.4% in comparison with the AMPLICOR test. Specificity of AMPLICOR PCR versus culture was 100%.
The AMPLICOR test proved to be easy to use. The whole procedure could be carried out in 4.5 h, whereas the in-house reverse transcription-PCR technique usually took 7 h. The difference in the times to complete the molecular tests is due to a 1-h difference in amplification and a 2-h difference in hybridization and detection.
The new reverse transcription-PCR assay was found to be sensitive and specific. Determination of analytical sensitivity of the AMPLICOR test resulted in detection of 0.1 or 1 TCID 50 of almost all enterovirus subtypes. Only echoviruses 22 and 23, which have been reported to be genetically distinct picornaviruses (1, 6) and are rarely isolated in CSF (17), could not be amplified with the primers used in the AMPLICOR test. Specific PCR products were not detected when a variety of nonenterovirus meningitis pathogens was tested; however, amplification products were detected from RNA extracts of five rhinovirus serotypes. Cross-reactivity between rhinoviruses and enteroviruses is produced by sequence homology between these two picornavirus groups. This cross-reactivity is of minor importance when testing CSF specimens, as there are no published reports of isolation of rhinovirus from CSF specimens. However, this would have an important impact on testing of nasal or pharyngeal swabs.
With clinical specimens, the specificity of the AMPLICOR Enterovirus Test versus culture was 100%. The commercial system gave superior sensitivity compared to culture. In eight culture-negative specimens, both molecular tests gave positive results. Culture sensitivity may be affected by inappropriate transport or storage of live organisms which does favor loss of viral infectivity but not necessarily detection by PCR. Furthermore, differences between culture systems may affect the results. In this study, CaCo-2 cells, which were shown to be superior compared with other cell lines for detection of several enteric viruses (14) , were used. The results from this study are consistent with other published reports in demonstrating that PCR is more sensitive than culture regardless of the cell line employed.
One specimen gave a false-negative result with the AMPLI-COR test. This may be due to the presence of inhibitors or the presence of a serotype not detected by the AMPLICOR Enterovirus Test. The in-house PCR used in this study is able to detect echovirus 23. Therefore, the specimen mentioned above might have contained echovirus 23.
In summary, application of the AMPLICOR Enterovirus Test proved to be a reliable tool for the detection of enteroviruses in CSF specimens. This assay gives more true-positive results than culture. Therefore, it is a good alternative to culture and should be readily accepted for use in a routine diagnostic laboratory. 
